Literature DB >> 18630028

Case of acute psychosis from herbal supplements.

Erica Peterson1, Adam Stoebner, Jay Weatherill, Eric Kutscher.   

Abstract

A recent study estimates that 15.2 percent of American adults use nonprescription dietary supplements for weight loss. Sale of ephedrine- and ephedrine-alkaloid-containing products was prohibited by the Food and Drug Administration in February 2004 after research demonstrated an increased risk of arrhythmia, mortality and hypertension following use of products containing these sympathomimetics. Subsequently, nutritional supplement manufacturers have turned to other products to promote weight loss. The following paper reports a case study of a 28-year-old woman with no prior psychiatric history who was hospitalized secondary to an acute psychotic episode. The patient reported starting several weight-loss and nutritional sports supplements approximately one week prior to admission. The relationship between the onset of psychosis and the initiation of the dietary supplements strongly suggests a correlation exists. Heightened consumer education regarding the contents of dietary supplements, along with their potential for causing adverse effects when used alone or in combination with other medications, is warranted. Patients who choose to take dietary supplements should be encouraged to inform their health care providers about the supplements they are taking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630028

Source DB:  PubMed          Journal:  S D Med        ISSN: 0038-3317


  2 in total

1.  An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction.

Authors:  Zhang-Jin Zhang; Qing-Rong Tan; Yao Tong; Xue-Yi Wang; Huai-Hai Wang; Lai-Ming Ho; Hei Kiu Wong; Yi-Bin Feng; Di Wang; Roger Ng; Grainne M McAlonan; Chuan-Yue Wang; Vivian Taam Wong
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

2.  Effectiveness of Traditional Chinese Medicineas as an Adjunct Therapy for Refractory Schizophrenia: A Systematic Review and Meta Analysis.

Authors:  Yan-Yan Wei; Wan-Fu Lin; Tian-Hong Zhang; Yun-Xiang Tang; Ji-Jun Wang; Mao-Feng Zhong
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.